Cardiovascular and Venous Thromboembolic Risk Associated With JAK Inhibitor Use in Patients With Immune-Mediated Inflammatory Skin Diseases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis
JAMA Dermatol 2023 Nov 01;[EPub Ahead of Print], JP Ingrassia, MH Maqsood, JM Gelfand, BN Weber, S Bangalore, KI Lo Sicco, MS GarshickFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.